Trial Profile

A Pharmacokinetic Dose Proportionality Study of OPL-002 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tamuzimod (Primary)
Indications Inflammatory bowel diseases; Ulcerative colitis
Focus Pharmacokinetics
Sponsors Oppilan Pharma

Most Recent Events

26 May 2021 Status changed from not yet recruiting to completed.
14 Sep 2020 Planned End Date changed from 25 Jul 2020 to 30 Oct 2020.
14 Sep 2020 Planned primary completion date changed from 25 Jul 2020 to 15 Oct 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com